China Cord Blood Soars as Rival Buyout Bid Valued 72% Higher

Updated on

China Cord Blood Corp. surged the most in a year as the stem-cell storage provider received a competing buyout bid that exceeded the one its biggest shareholder made in April by 72 percent.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.